Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.00.

A number of brokerages recently commented on TLX. Citigroup started coverage on shares of Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective on the stock. HC Wainwright decreased their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Finally, UBS Group lowered their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the second quarter worth approximately $217,000. JPMorgan Chase & Co. purchased a new position in Telix Pharmaceuticals during the third quarter worth approximately $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $297,000.

Telix Pharmaceuticals Price Performance

Telix Pharmaceuticals stock opened at $9.82 on Tuesday. Telix Pharmaceuticals has a fifty-two week low of $8.76 and a fifty-two week high of $30.36. The stock’s fifty day moving average is $10.08 and its two-hundred day moving average is $12.59.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.